Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket?  

作　　者：Robert S O'Neill Alina Stoita 

机构地区：[1]Department of Gastroenterology,St Vincent's Hospital Sydney,Sydney 2010,Australia [2]St George and Sutherland Clinical School,Faculty of Medicine,University of New South Wales,Sydney 2010,Australia [3]St Vincent’s Clinical School,Faculty of Medicine,University of New South Wales,Sydney 2010,Australia

出　　处：《World Journal of Gastroenterology》2021年第26期4045-4087,共43页世界胃肠病学杂志（英文版）

摘　　要：Pancreatic cancer(PC)is a leading cause of cancer related mortality on a global scale.The disease itself is associated with a dismal prognosis,partly due to its silent nature resulting in patients presenting with advanced disease at the time of diagnosis.To combat this,there has been an explosion in the last decade of potential candidate biomarkers in the research setting in the hope that a diagnostic biomarker may provide a glimmer of hope in what is otherwise quite a substantial clinical dilemma.Currently,serum carbohydrate antigen 19-9 is utilized in the diagnostic work-up of patients diagnosed with PC however this biomarker lacks the sensitivity and specificity associated with a gold-standard marker.In the search for a biomarker that is both sensitive and specific for the diagnosis of PC,there has been a paradigm shift towards a focus on liquid biopsy and the use of diagnostic panels which has subsequently proved to have efficacy in the diagnosis of PC.Currently,promising developments in the field of early detection on PC using diagnostic biomarkers include the detection of microRNA(miRNA)in serum and circulating tumour cells.Both these modalities,although in their infancy and yet to be widely accepted into routine clinical practice,possess merit in the early detection of PC.We reviewed over 300 biomarkers with the aim to provide an in-depth summary of the current state-of-play regarding diagnostic biomarkers in PC(serum,urinary,salivary,faecal,pancreatic juice and biliary fluid).

关 键 词：Pancreatic cancer Cancer Biomarkers DIAGNOSTIC Review 

分 类 号：R735.9[医药卫生—肿瘤]